- Home
- THAR vs INM Comparison
THAR vs INM Comparison
Compare THAR & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- INM
- Stock Information
- Founded
- THAR 2017
- INM 1981
- Country
- THAR United States
- INM Canada
- Employees
- THAR N/A
- INM N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- INM Health Care
- Exchange
- THAR Nasdaq
- INM Nasdaq
- Market Cap
- THAR 3.3M
- INM 3.2M
- IPO Year
- THAR 2022
- INM N/A
- Fundamental
- Price
- THAR $1.51
- INM $2.87
- Analyst Decision
- THAR Strong Buy
- INM
- Analyst Count
- THAR 1
- INM 0
- Target Price
- THAR $17.00
- INM N/A
- AVG Volume (30 Days)
- THAR 26.3K
- INM 4.1M
- Earning Date
- THAR 05-12-2025
- INM 05-12-2025
- Dividend Yield
- THAR N/A
- INM N/A
- EPS Growth
- THAR N/A
- INM N/A
- EPS
- THAR N/A
- INM N/A
- Revenue
- THAR N/A
- INM $4,920,990.00
- Revenue This Year
- THAR N/A
- INM N/A
- Revenue Next Year
- THAR N/A
- INM N/A
- P/E Ratio
- THAR N/A
- INM N/A
- Revenue Growth
- THAR N/A
- INM N/A
- 52 Week Low
- THAR $0.95
- INM $1.72
- 52 Week High
- THAR $6.39
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- THAR 54.61
- INM 50.24
- Support Level
- THAR $1.41
- INM $2.74
- Resistance Level
- THAR $1.64
- INM $3.45
- Average True Range (ATR)
- THAR 0.11
- INM 0.70
- MACD
- THAR 0.01
- INM 0.03
- Stochastic Oscillator
- THAR 63.86
- INM 9.40
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.